Exelixis (EXEL) Announces U.S. FDA Accepts sNDA for CABOMETYX in Previously Treated Advanced Hepatocellular Carcinoma
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
